First-Line Treatment for RA Flare
For an acute rheumatoid arthritis flare, immediately initiate systemic glucocorticoids (prednisone 30-35 mg/day for 3-5 days) or intra-articular glucocorticoid injection for localized joint involvement, while simultaneously optimizing or escalating your disease-modifying antirheumatic drug (DMARD) therapy. 1
Acute Flare Management
The immediate priority is controlling the inflammatory flare itself:
First-Line Options for Acute Symptom Control:
- Systemic glucocorticoids: Prednisone 30-35 mg/day (or equivalent) for 3-5 days 1
- Intra-articular glucocorticoid injection: For monoarticular or oligoarticular flares 1, 2
- NSAIDs: At minimum effective dose for shortest duration, after evaluating GI, renal, and cardiovascular risks 1
Important caveat: While glucocorticoids effectively reduce pain, swelling, and structural progression, they should be used at the lowest dose necessary as temporary (<6 months) adjunctive treatment due to cumulative side effects 1. The 2017 EULAR guidelines specifically emphasize this temporal limitation.
Concurrent DMARD Strategy
The flare signals inadequate disease control—you must address the underlying treatment regimen simultaneously:
If Patient is DMARD-Naive or on Suboptimal Therapy:
- Start or optimize methotrexate to 15-25 mg/week (the "anchor drug") 1, 3
- Consider switching to subcutaneous methotrexate if oral form shows inadequate response or GI intolerance 4, 2
If Patient is Already on Methotrexate Monotherapy:
At 3-6 months, if disease activity persists (SDAI >11 or CDAI >10):
Two pathways based on prognostic factors 4, 5:
Without poor prognostic factors: Add triple conventional synthetic DMARD therapy (methotrexate + sulfasalazine + hydroxychloroquine) 4, 5
With poor prognostic factors (RF/ACPA positive, high disease activity, early joint damage): Add a biologic DMARD (TNF inhibitor, abatacept, tocilizumab) or JAK inhibitor 4, 5, 3
If Patient is Already on Biologic Therapy:
- Switch to an alternative biologic agent, preferably with a different mechanism of action 4
- Consider abatacept after TNF inhibitor failure (proven efficacy in this setting) 4
Critical Timing Considerations
The 2017 EULAR guidelines establish clear timeframes 1:
- Assess improvement at 1-3 months
- Target achievement (remission or low disease activity) should occur by 6 months
- If no improvement by 3 months or target not reached by 6 months, therapy must be adjusted
Common Pitfalls to Avoid
Don't treat the flare in isolation: A flare indicates your background DMARD therapy is failing. Treating only with glucocorticoids without addressing the underlying treatment strategy leads to recurrent flares 6.
Don't delay DMARD escalation: The evidence strongly supports early aggressive treatment. Patients with high disease activity at 3 months refractory to optimized methotrexate have low probability of achieving remission at 1 year without combination therapy or biologics 4.
Don't continue glucocorticoids long-term: While effective for acute control, prolonged use (>6 months) carries significant toxicity that outweighs benefits 1, 2.
Don't use NSAIDs as monotherapy: NSAIDs are purely symptomatic and do not modify disease progression 1.
Monitoring After Flare Treatment
Reassess disease activity at 1-3 month intervals using composite measures (SDAI, CDAI, or DAS28) that include:
- Tender and swollen joint counts
- Patient and physician global assessments
- Acute phase reactants (ESR, CRP) 1
The goal remains clinical remission (SDAI ≤3.3 or CDAI ≤2.8), though low disease activity (SDAI ≤11 or CDAI ≤10) may be acceptable in patients with severe, refractory, or long-established RA 4.